2016
DOI: 10.1186/s12888-016-0785-x
|View full text |Cite
|
Sign up to set email alerts
|

Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort

Abstract: BackgroundMajor Depressive Disorder (MDD) is among the most prevalent and disabling medical conditions worldwide. Identification of clinical and biological markers (“biomarkers”) of treatment response could personalize clinical decisions and lead to better outcomes. This paper describes the aims, design, and methods of a discovery study of biomarkers in antidepressant treatment response, conducted by the Canadian Biomarker Integration Network in Depression (CAN-BIND). The CAN-BIND research program investigates… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
158
0

Year Published

2017
2017
2023
2023

Publication Types

Select...
9

Relationship

6
3

Authors

Journals

citations
Cited by 121 publications
(158 citation statements)
references
References 55 publications
0
158
0
Order By: Relevance
“…All patients from cohort 2 (RPCT2) were recruited as part of the Canadian Biomarker Integration Network in Depression (CAN-BIND) study19. (Fig.…”
Section: Resultsmentioning
confidence: 99%
“…All patients from cohort 2 (RPCT2) were recruited as part of the Canadian Biomarker Integration Network in Depression (CAN-BIND) study19. (Fig.…”
Section: Resultsmentioning
confidence: 99%
“…In this study, we assessed test–retest reliability of an emotional conflict task in healthy comparison participants collected within a Canadian Biomarker Integration Network in Depression (CAN‐BIND) protocol (Kennedy et al, ; Lam et al, ). The Canadian Biomarker Integration Network in Depression (CAN‐BIND‐1) Program aims to identify biomarkers of antidepressant treatment response in patients with major depressive disorder (MDD).…”
Section: Introductionmentioning
confidence: 99%
“…The CAN-BIND research program investigates and identifies neuroimaging, electrophysiological, molecular and clinical biomarkers to predict outcomes in patients with MDD treated with antidepressant medication [151]. The stratification of patients on the basis of genetic biomarkers may be facilitated by further developments in genetic testing.…”
Section: Five-year Viewmentioning
confidence: 99%